Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS

v3.8.0.1
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 3,465 $ 7,522
Restricted cash 361 361
Receivables 27 65
Contract assets 291 0
Prepaid expenses and other current assets 605 362
Total current assets 4,749 8,310
Property and equipment, net 541 595
Total assets 5,290 8,905
Current liabilities:    
Accounts payable 345 821
Accrued clinical trials expenses 408 289
Other accrued liabilities 556 354
Deferred revenue 1,409 0
Current portion of long-term debt 0 3,000
Total current liabilities 2,718 4,464
Long-term debt, net of debt discount 3,418 3,584
Total liabilities 6,136 8,048
Commitments and contingencies
Stockholders’ equity (deficit):    
Common stock, at amounts paid-in 297,855 297,855
Additional paid-in capital 27,175 26,273
Accumulated deficit (325,876) (323,271)
Total stockholders’ equity (deficit) (846) 857
Total liabilities and stockholders’ equity (deficit) $ 5,290 $ 8,905